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Small-molecule kinase inhibitors have typically
been designed to inhibit wild-type kinases rather
than the mutant forms that frequently arise in
diseases such as cancer. Mutations can have
serious clinical implications by increasing kinase
catalytic activity or conferring therapeutic resis-
tance. To identify opportunities to repurpose inhib-
itors against disease-associated mutant kinases,
we conducted a large-scale functional screen of
183 known kinase inhibitors against 76 recombi-
nant mutant kinases. The results revealed lead
compounds with activity against clinically im-
portant mutant kinases, including ALK, LRRK2,
RET, and EGFR, as well as unexpected opportu-
nities for repurposing FDA-approved kinase inhibi-
tors as leads for additional indications. Further-
more, using T674I PDGFRa as an example, we
show how single-dose screening data can provide
predictive structure-activity data to guide subse-
quent inhibitor optimization. This study provides
a resource for the development of inhibitors
against numerous disease-associated mutant ki-
nases and illustrates the potential of unbiased
profiling as an approach to compound-centric in-
hibitor development.INTRODUCTION
Kinases participate in many signaling pathways, including those
involved in cell proliferation, growth, metabolism, apoptosis, and
differentiation. Not surprisingly, kinases are mutationally acti-
vated in a number of disorders. Small-molecule inhibitor devel-
opment represents a major focus of drug discovery efforts to
treat these disorders. Well over two dozen kinase inhibitors are
approved for clinical use by the Food and Drug Administration
(FDA) andmany others are in clinical development. A major chal-772 Cell Reports 14, 772–781, February 2, 2016 ª2016 The Authorslenge is target promiscuity because most small-molecule kinase
inhibitors target the ATP binding site, a highly conserved region
in kinases. Therefore, compounds designed to target this site
often inhibit other kinases as well (Zhang et al., 2009). Indeed,
several recent large-scale screens have revealed numerous
off-target effects for both commonly used research tool com-
pounds and clinical kinase inhibitors (Anastassiadis et al.,
2011; Davis et al., 2011; Fabian et al., 2005; Gao et al., 2013;
Karaman et al., 2008). In some cases, these studies have identi-
fied unexpected kinase targets inhibited more potently by a
compound than that compound’s intended target. Therefore,
broad profiling of compounds against kinase libraries can be
used for repurposing existing agents based on unexpected ac-
tivity against unrelated kinases.
One particularly exciting application of broad profiling is the
identification of potent and selective inhibitors ofmutant kinases.
Disease-associated kinase domain mutations can increase ki-
nase activity. Well characterized examples of activating, dis-
ease-associated kinase mutations are deletions in exon 19 of
the epidermal growth factor receptor (EGFR) present in non-
small-cell lung cancer (NSCLC). Normally, ligand binding pro-
motes EGFR dimerization and auto-activation. Deletions in
exon 19 promote EGFR dimerization and auto-activation in the
absence of ligand, leading to constitutive kinase activity (Ladanyi
and Pao, 2008).
Although exon 19-deleted mutants of EGFR are generally sen-
sitive to erlotinib and gefitinib, therapeutic use of kinase inhibi-
tors can select for mutations that render these kinases resistant
to these therapies. A common hotspot for resistance mutations
in many kinases is the gatekeeper residue located within the
ATP-binding pocket. Gatekeeper mutations can enhance ATP
binding affinity or sterically restrict inhibitor binding, thereby
reducing inhibitor potency. The T790M gatekeeper residue mu-
tation in EGFR, for example, increases ATP affinity and confers
erlotinib and gefitinib resistance (Pao et al., 2005; Yun et al.,
2008). Another classic example is the T315I mutation in the
BCR-ABL kinase, which confers imatinib resistance (Gorre
et al., 2001). In some instances, resistance mutations also
enhance kinase catalytic activity (Azam et al., 2008).
In recent years, improved sequencing technologies have facil-
itated the identification of activating and resistance mutations in
Figure 1. The Mutated Kinases Represent a Diverse Set of Kinase
Variants
(A) Distribution of kinase variants containing alterations in the kinase domain
versus outside of the kinase domain.
(B) Distribution by mutation type.
(C) Disease association of kinase variants. ‘‘Laboratory-generated’’ reflects
mutations that have not been associated with any physiological disorders.
A complete list of mutated kinases is available in Table S1.kinases. We have previously performed a target-blind screen of
178 compounds against a panel of 300 wild-type protein kinases
to examine kinase inhibitor selectivity (Anastassiadis et al.,
2011). Although this dataset provided a wealth of information
about clinical kinase inhibitors, compounds in clinical develop-
ment, and research tool compounds, it did not provide insights
into inhibition of clinically relevant mutant kinases. Here we
screened an overlapping collection of 183 small-molecule com-
pounds against a panel of 76 mutated kinases derived from 21
cognate wild-type kinases. The resulting dataset comprises
over 13,000 mutant kinase-compound pairs, almost an order
of magnitude larger than those of prior studies (Davis et al.,
2011; Uitdehaag et al., 2014). These mutated kinases includeCmany drug-resistant kinases and activating disease-associated
mutant kinases. The data not only faithfully reproduced known
kinase/inhibitor interactions but also revealed several targets
and opportunities for repurposing FDA-approved kinase inhibi-
tors against disease-relevant targets. We found an inhibitor of
the highly resistant T790M EGFR mutant that, although related
structurally and mechanistically, is more selective than afatinib,
an FDA-approved agent. We also describe a series of clinical
compounds that inhibit imatinib-resistant T674I platelet-derived
growth factor receptor a (PDGFRa) and demonstrate how the
data can be used not only to identify lead inhibitor scaffolds
against kinases of clinical interest but also to generate predictive
structure-activity hypotheses for lead compounds that can guide
their subsequent optimization. We further anticipate that this da-
taset will serve as a useful resource for the development of com-
pounds active against other disease-associated kinase variants.
RESULTS
Screening of a Broad Panel of Mutated Kinases
A total of 183 small-molecule compoundswere screened against
76 mutant kinases (Experimental Procedures; Table S1) using
the HotSpot radiometric filter-binding kinase assay (Anastassia-
dis et al., 2011). This functional assay directly measures kinase-
catalyzed transfer of a radiolabeled phosphate from ATP to a
relevant protein or peptide substrate. The compounds screened
included 12 that are FDA-approved. Other compounds included
those in clinical development and research tool compounds. All
compounds were screened in duplicate at 500 nM in the pres-
ence of 10 mM ATP to reveal weak off-target activities and for
consistency with our previous analysis with wild-type kinases
(Anastassiadis et al., 2011).
The vast majority of the mutated kinases contain alterations in
the kinase domain (Figure 1A). Most variants are single amino
acid changes, but there are also variants with one in-frame dele-
tion each (d746–750 EGFR and d752–759 EGFR), three variants
containing two amino acid changes (L858R/T790M EGFR,
V559D/V654A C-KIT, and V559D/T670I C-KIT), an internal tan-
dem duplication (FLT3 ITD), and three variants containing both
an in-frame deletion and an amino acid change (d746–750/
T790M EGFR, d747–749/A750P EGFR, and d747–752/P753S
EGFR;Figure1B).Over80%of the kinasesarecancer-associated
variants documented by the COSMIC database (Forbes et al.,
2011) or elsewhere (Figure 1C). The remaining kinases represent
variants present in other diseases or laboratory-generated muta-
tions. One-third of the kinase constructs represent acquired
resistance mutations found in patients who relapse following
treatment. The kinases arise from a total of 21 corresponding
wild-type kinases, comprising 16 tyrosine and five serine/threo-
nine kinases. The over-representation of tyrosine kinases com-
pared with their representation in the human kinome reflects the
historical focus on this kinase subfamily in drug discovery.
The data comprise 13,875mutant kinase/compound pairs. For
each kinase/compound interaction, we calculated the percent
remaining kinase activity relative to a control reaction in the
presence of vehicle (dimethyl sulfoxide). Each measurement
was performed in duplicate, and 33 discrepant data pairs
(0.2%of the dataset) were identified and eliminated as describedell Reports 14, 772–781, February 2, 2016 ª2016 The Authors 773
Figure 2. Large-Scale Screen of Kinase/Compound Pairs
Shown is a heatmap representing the distribution of remaining kinase activities for kinase/compound pairs in this study as well as data for their wild-type
cognates, as reported previously (Anastassiadis et al., 2011). The 183 compounds in the screen were subjected to hierarchical clustering, as shown by the
dendrogram at the top. The 76 mutant kinases are grouped according to cognate wild-type kinase. Only kinase families with three or more members are labeled
for clarity. A fully labeled version of this figure is provided in Figure S1; and the complete dataset is available in Table S2 and can be searched at the Kinase
Inhibitor Resource (kir.fccc.edu).previously (Anastassiadis et al., 2011). Importantly, we have
shown previously that single-dose screening from this platform
is recapitulated reliably in follow-up dose-response experiments
(Anastassiadis et al., 2011), and we confirm this reproducibility
again below. The data are presented as a heatmap in Figure 2
(a higher-resolution figure with labels is available as Figure S1,
and the complete dataset is available in Table S2 and can be
queried at the Kinase Inhibitor Resource [kir.fccc.edu]) and
include data reported previously for the corresponding wild-
type forms for comparison (Anastassiadis et al., 2011). The com-
pounds exhibited awide range of selectivity. 39%of compounds
did not inhibit any mutant kinase by >50%, whereas 7.1% of
compounds inhibited half or more of the mutant kinases by
>50%.Only 3.8%of compounds inhibited a singlemutant kinase
target by >50%.
For the most part, mutant kinases are inhibited by compounds
that also inhibit their cognate wild-type kinases (Anastassiadis
et al., 2011). However, resistance mutations and mutations
that enhance kinase sensitivity to particular compounds are
also present. Also, a number of unexpected compound/kinase
interactions were revealed from the single-dose screening data
that were subsequently verified in dose-response experiments
and warrant further investigation. For example, we found that
the tool compounds Flt-3 inhibitor and Jak3 inhibitor II also
inhibit Parkinson’s disease-associated LRRK2 mutants (Figures
S2A and S2B; Table S3). Also, we identified bosutinib isomer as774 Cell Reports 14, 772–781, February 2, 2016 ª2016 The Authorsan inhibitor of crizotinib-resistant L1196M ALK (Figure S2C;
Table S3). Additionally, we showed that tozasertib, a serine/thre-
onine kinase inhibitor, can inhibit mutants of the RET tyrosine ki-
nase (Figure S2D; Table S3). Below we discuss in greater detail
just two examples of previously undescribed compound-kinase
interactions, including a highly selective inhibitor of the T790M
EGFR mutation that is structurally similar to afatinib but with
fewer non-EGFR family targets and several clinical kinase inhib-
itors that inhibit imatinib-resistant T674I PDGFRa.
Comparison with Previous Studies
A small proportion of the analyzed mutant kinase/compound
pairs overlaps with previous large-scale screens (Tables S4
and S5). 1.9% of the mutant kinase/compound pairs overlapped
with a previous study that utilized either ELISA or mobility shift
assays to measure inhibition of kinase activity by 1 mM com-
pound (Uitdehaag et al., 2014). For kinase/compound pairs
that overlapped with our study (Table S4), there was general
agreement, with the majority of overlapping pairs (66%) display-
ing either no inhibition or nearly complete inhibition of kinase
activity in both studies (boxed regions in Figure 3A). Kinase/com-
pound pairs with intermediate levels of inhibition (values outside
of the boxed regions in Figure 3A) showed greater discrepancies,
likely because of the sensitivity of the assay to small differences
in compound concentration near the IC50 value or differences in
themethods or protein constructs employed. Overall, 79%of the
Figure 3. Comparison of Overlapping Data between This Screen and Previous Studies
(A) Percent inhibition from the Uitdehaag et al. (2014) study was extrapolated to 500 nM, as described previously (Anastassiadis et al., 2011), and was plotted
against percent inhibition in this study. Dashed boxes indicate compound/kinase interactions that fall within 20% of complete inhibition or 20% of no inhibition.
The dashed line denotes the line of identity between the two studies. The complete list of overlapping pairs between these studies is given in Table S4. WT, wild-
type. (B) Remaining kinase activity from this screen was plotted against binding affinities from Davis et al. (2011). The solid line represents a fit to a standard
sigmoidal dose-response curve. The dashed line represents a theoretical curve for remaining kinase activity derived as described in Anastassiadis et al. (2011).
The complete list of overlapping pairs between these studies is given in Table S5.overlapping pairs exhibit either no inhibition, nearly complete in-
hibition, or show remaining kinase activity values within 20% of
each other between the studies when the data from Uitdehaag
et al. (2014) are extrapolated to 500 nM compound concentra-
tion according to the Cheng-Prusoff equation (Figure 3A).
A fraction (2.7%) of the mutant kinase/compound pairs in our
study also overlap with another large-scale kinase/compound
interaction study (Davis et al., 2011) that utilized a competitive
binding assay rather than an enzymatic assay. For the overlap-
ping pairs between the two screens (Table S5), the percent re-
maining kinase activity measured in the functional assay and
the affinities measured in the binding assay were compared us-
ing the Cheng-Prusoff equation (Figure 3B). The results of both
studies are highly congruent, with compounds exhibiting high-
affinity binding also generally showing potent inhibition in the
functional assay. In some cases, however, the results of the
two assays differed significantly (e.g., C-KIT V559D/V654A-ma-
sitinib and C-KIT A829P-staurosporine). In these cases, the
binding assay reported a KD of <5 nM, but only moderate kinase
inhibition was observed at 500 nM. Such discrepancies could
reflect differences in the kinase constructs used in the two
studies or, more interestingly, differences in kinase activation
state, perhaps resulting from the presence (this study) or
absence (Davis et al., 2011) of ATP in the screen. These discrep-
ancies warrant further investigation. However, the overall
congruence of these studies, which utilize distinct assays to
monitor compound-kinase interactions, supports the reliability
of the data.
Inhibition of a Resistant Target, T790M EGFR
Several EGFR mutations found in NSCLC lead to increased ki-
nase activity and, in some cases, ligand-independent activation
(Pines et al., 2010). Our mutant kinase panel contains 11 variant
forms of EGFR, eight of which are clinically relevant activated
forms, including exon 19 deletion mutations (d746–750, d747–
749/A750P, d747–752/P753S, and d752–759) and activatingCpoint mutations (G719C, G719S, L858R, and L861Q). Together,
these mutations account for >90% of all activating EGFR mu-
tants reported in NSCLC (Ladanyi and Pao, 2008). Consistent
with previous studies, we found that these EGFR mutants were
sensitive to the FDA-approved EGFR inhibitors erlotinib and ge-
fitinib (Figure 4A).
Although these activated EGFR variants are generally sensi-
tive to erlotinib and gefitinib, acquired resistance occurs in
50% of patients treated with these agents (Balak et al., 2006;
Carey et al., 2006; Paez et al., 2004). About half of the patients
with acquired resistance harbor the T790M mutation (Kosaka
et al., 2006). In addition, 5% of untreated NSCLC patients
also express T790M EGFR and have primary resistance to
erlotinib and gefitinib (Bell et al., 2005). Our mutant kinase panel
includes three erlotinib/gefinitib-resistant EGFR forms, all of
which contain the T790M mutation (T790M, T790M/L858R,
and d746–750/T790M). T790M EGFR mutants were among the
most inhibitor-resistant kinases in our screen. Although 22% of
the screened compounds inhibited at least one of the EGFR
mutants by at least 50%, only 7% of the screened compounds
inhibited at least one of the T790M EGFR mutants by the same
amount (Figures 4A and 4B; Table S2). One of these, afatinib,
is an FDA-approved EGFR inhibitor for NSCLCwith known activ-
ity against T790MEGFR (Katakami et al., 2013; Li et al., 2008). As
expected, afatinib potently inhibited T790M and other EGFRmu-
tants in the panel (Figure 4A).
One additional compound showed similarly potent and selec-
tive inhibitory activity against the T790M mutant: EGFR/ErbB2/
ErbB4 inhibitor (CAS no. 881001-19-0; Figures 4B and 4C; Table
S2; Figure S3). This compoundwas developed to target the ErbB
family (Klutchko et al., 2006), but its potency against EGFR var-
iants harboring the T790M mutation has not been reported pre-
viously. Surprisingly, comparing its chemical structure to that of
afatinib revealed striking similarities (Figure 4C). Both com-
pounds are inhibitors that covalently bind to cysteine 797 in
EGFR and were developed through two independent drugell Reports 14, 772–781, February 2, 2016 ª2016 The Authors 775
Figure 4. The EGFR/ErbB2/ErbB4 Inhibitor and Afatinib Inhibit T790M EGFR
(A) Heatmap representing compounds that inhibit any EGFR mutants with less than 50% remaining kinase activity. The coloring is as shown in Figure 2.
(B) Heatmap representing compounds that inhibit one or more of the T790M EGFR mutants with less than 50% remaining kinase activity. The EGFR family is
indicated with the bracket, and the EGFR variants containing T790M are indicated with asterisks. An explicitly labeled heatmap is provided in Figure S3.
(C) Chemical structures of the EGFR/ErbB2/ErbB4 inhibitor and afatinib.discovery efforts (Eskens et al., 2008; Klutchko et al., 2006).
Although both compounds inhibit all T790M EGFR kinases with
low nanomolar IC50 values (Figure S4), the EGFR/ErbB2/ErbB4
inhibitor exhibited greater selectivity than afatinib based on its
Gini coefficient, a metric of kinase inhibitor selectivity (Graczyk,
2007). The Gini coefficient for the EGFR/ErbB2/ErbB4 inhibitor
is 0.791 versus 0.712 for afatinib when screened against a panel
of 300 wild-type kinases (Table S6). Of the ten kinases inhibited
by the EGFR/ErbB2/ErbB4 inhibitor by more than 50%, eight776 Cell Reports 14, 772–781, February 2, 2016 ª2016 The Authorshave a Cys residue in the position analogous to EGFR Cys797
(BLK, BMX/ETK, BTK, EGFR, ERBB2, ERBB4, JAK3, and TXK)
whereas two (CLK3 and RIPK2) do not. In contrast, of the 19 ki-
nases inhibited by afatinib by more than 50%, only six (BLK,
BTK, EGFR, ERBB2, ERBB4, and TXK) have a Cys residue at
this position whereas 13 (C-MER, C-SRC, EPHA6, EPHB4,
FGR, HCK, IRAK1, LCK, LYN, MNK1, MNK2, P38a/MAPK14,
and YES/YES1) do not. These data imply that afatinib inhibits
these kinases without forming a covalent adduct at the position
Figure 5. Several Clinical Kinase Inhibitors Target T674I PDGFRa
(A) Dose-response curves based on in vitro kinase assays against recombinant T674I PDGFRa. IC50 values are given in Table S3. Error bars represent SEM.
(B) Cell viability measurements of Ba/F3 cells expressing WT FIP1L1-PDGFRa in the presence of the same compounds tested in (A). Error bars represent SEM.
(C) The same as (B) but for Ba/F3 cells expressing T674I FIP1L1-PDGFRa.
(D) IC50 values for the cell viability measurements in (B) and (C).analogous to EGFR Cys797. Such a mechanism could explain
the lower selectivity of afatinib compared with the EGFR/
ErbB2/ErbB4 inhibitor. The potency and selectivity of the
EGFR/ErbB2/ErbB4 inhibitor suggests that it warrants further
study.
Repurposing Clinical Kinase Inhibitors to Target T674I
PDGFRa
Repurposing clinical agents for use against additional kinases
beyond the intended target is attractive because the safety of
these agents has already been established. We were therefore
particularly interested in targets for compounds in our panel
that are either FDA-approved or in clinical development. One
target of several clinical agents was the T674I mutant of
PDGFRa. Thismutation occurs clinically in the context of a fusion
protein resulting from a chromosomal translocation that joins the
first 233 amino acids of the Fip1-like 1 protein (FIP1L1) and the
last 523 amino acids, including the kinase domain, of PDGFRa
(Cools et al., 2003). Kinase activity of the resultant FIP1L1-
PDGFRa protein is associated with hypereosinophilic syndrome
(HES) (Cools et al., 2003), a myeloproliferative disorder of eosin-
ophils that can progress to chronic eosinophilic leukemia (CEL).CPatients expressing wild-type FIP1L1-PDGFRa respond to ima-
tinib, but acquisition of the T674I mutation renders the cells im-
atinib-resistant (Cools et al., 2003). Several kinase inhibitors,
including sorafenib and nilotinib, have shown only limited clinical
efficacy in imatinib-resistant HES and CEL (von Bubnoff et al.,
2006; Lierman et al., 2006, 2009; Metzgeroth et al., 2012). Pona-
tinib, a multi-targeted tyrosine kinase inhibitor, has shown prom-
ising activity in cell lines expressing T674I FIP1L1-PDGFRa but
has not yet been evaluated in patients with this mutation (Sado-
vnik et al., 2014). Therefore, there is a need for second-line ther-
apies for HES/CEL associated with T674I FIP1L1-PDGFRa.
Consistent with previous studies (Cools et al., 2003), our
screening data indicated that T674I PDGFRa is substantially
resistant to imatinib (IC50 = 1.48 mM; Figure 5A; Table S3). Our
screen also revealed several additional clinical agents, including
dovitinib, erlotinib, pazopanib, sunitinib, and sorafenib, that in-
hibited T674I PDGFRa by >90% at the 500 nM screening con-
centration (Table S2). Only sorafenib and sunitinib have been
noted previously to be active against T674I FIP1L1-PDGFRa
(Lierman et al., 2006; Sadovnik et al., 2014). Dose-response ex-
periments were conducted against recombinant T674I PDGFRa
with each of these compounds as well as with gefitinib, whichell Reports 14, 772–781, February 2, 2016 ª2016 The Authors 777
shares structural similarity with erlotinib. Of all of these agents,
sunitinib was the most potent (IC50 = 1.17 nM; Figure 5A; Table
S3), although all, with the exception of gefitinib, exhibited low
nanomolar IC50 values consistent with the primary screening
data.
We then tested whether or not these compounds inhibit the
proliferation of Ba/F3 cell lines that are dependent on either
wild-type FIP1L1-PDGFRa or T674I FIP1L1-PDGFRa for growth
(Cools et al., 2003; Figures 5B–5D). As expected (Cools et al.,
2003), imatinib was much more effective at inhibiting the growth
of wild-type FIP1L1-PDGFRa Ba/F3 cells (IC50 = 1.91 nM) than
T674I FIP1L1-PDGFRa cells (IC50 = 13.6 mM). Sunitinib potently
inhibited T674I FIP1L1-PDGFRa cell growth (IC50 = 45.2 nM),
consistent with the in vitro data and a recent report (Sadovnik
et al., 2014), and two additional FDA-approved agents, sorafenib
and pazopanib, showed significant anti-proliferative activity
(144 nM and 3.17 mM, respectively). These results argue for im-
mediate consideration of these agents as potential second-line
therapies for imatinib-resistant CEL. In addition, dovitinib also
potently inhibited growth of the mutant-expressing cells (IC50 =
436 nM), although this compound has not yet received FDA
approval. Although most tested agents showed more potent in-
hibition of wild-type FIP1L1-PDGFRa-expressing cells than the
T674I mutant (Figures 5B–5D), gefitinib showed comparable
anti-proliferative activity against both cell lines (9.34 mM versus
6.20 mM). More strikingly, erlotinib inhibited T674I mutant cells
more than 8-fold more potently than cells expressing the wild-
type fusion (1.64 mM versus 14.5 mM). This unexpected selective
activity against T674I demonstrates a potential therapeutic win-
dow for activity against the cancer-associated mutation com-
pared with the wild-type form that could be exploited further
through additional medicinal chemistry as discussed below.
Prediction of Chemical Modifications that Affect the
Potency of 4-Anilinoquinazolines against T674I PDGFRa
Primary screening hits must generally be optimized to increase
their potency as lead compounds. However, structurally related
compounds in the screening library can often provide important
clues regarding the underlying structure-activity relationship and
guide medicinal chemistry efforts. 13 of the 183 compounds
screened in this study contain the 4-anilinoquinazoline core
found in erlotinib (Table S7). Interestingly, these compounds ex-
hibited a wide range of inhibitory potency against T674I PDGFRa
(Table S7). Because structure-guided design of inhibitors against
PDGFRa is not possible because of the lack of high-resolution
structural data for this kinase, we examined whether our
screening data could be used to predict chemical modifications
to 4-anilinoquinazoline that could guide the development of
more potent anilinoquinazolines with activity against T674I
PDGFRa.
All of the 4-anilinoquinazoline compounds included in the
screen were substituted at either the meta and/or para positions
of the aniline ring. Only vandetanib contained a substituent at the
ortho position. To determine whether substitutions at themeta or
at the para position were generally associated with more potent
T674I inhibition, we compared the single-dose activity of all 13
4-anilinoquinazoline compounds (Figure 6A). Although these
compounds differed at other positions as well, we observed a778 Cell Reports 14, 772–781, February 2, 2016 ª2016 The Authorsmodestly greater average inhibitory activity among compounds
containing substituents at the meta position. In addition, larger
substituents at the para position were associated with lower
potency (Figure 6B). Halogens (either Br or Cl) were often present
at the meta position of the aniline ring, and compounds with Br
at this position had, on average, a slightly greater potency
compared with those containing Cl, suggesting that either
electronegativity and/or atomic size had an effect on compound
potency toward T674I PDGFRa (Figure 6C). We next consid-
ered whether these aggregate trends revealed by the single-
dose profiling data reflected true underlying structure-activity
relationships.
To rigorously test our structure-activity hypotheses in the
context of otherwise identical 4-anilinoquinazoline compounds,
weobtainedavarietyofderivativesof6,7-dimethoxy-4-anilinoqui-
nazoline (Figure 6D), confirmed their identity and purity by liquid
chromatography-mass spectrometry (LC-MS), and measured
inhibitory activity at multiple doses against T674I PDGFRa. To
test whether meta substitutions are generally preferred over
para substitutions, we compared the potency ofWHI-P180 (com-
pound 1) and Janex 1 (compound 2). Confirming our prediction,
the meta-substituted compound 1 was indeed more potent by a
factor of 2-fold (Figure 6E).
We next tested whether a series of compounds with increas-
ingly larger para substituents (Janex 1 [compound 2] < Src
kinase inhibitor I [compound 3] < EGFR/ErbB2 inhibitor [com-
pound 4]) showed decreased inhibitory potency. Although
compound 3 was several fold more potent than compound 4,
as predicted, compound 2 was approximately 2-fold less potent
than compound 3 (Figure 6F), possibly because of confounding
effects of the hydrogen-bonding capacity of compound 2. These
observations highlight the complexity of validating structure-ac-
tivity hypotheses from a limited numbers of compounds, but,
collectively, our data suggest a general trend that larger substit-
uents at the para position of the aniline ring decrease compound
potency.
Last, we examined whether less electronegative/larger halo-
gens have enhanced potency compared with more electronega-
tive/smaller halogen atoms at the meta position of the aniline
ring of the 6,7-dimethoxy-4-anilinoquinazoline pharmacophore.
Although the Br-substituted PD153035 (compound 6) and
the Clsubstituted AG-1478 (compound 5) had similar IC50
values for inhibition of T674I PDGFRa kinase activity, these com-
pounds were approximately 1.5-fold more potent than the more
electronegative, smaller fluoride-substituted compound 7, in
agreement with our prediction (Figure 6G). Collectively, these
comparisons demonstrate that the screening data presented in
this study can be used to infer chemical modifications that
enhance inhibitor potency in the absence of any structural data
for a kinase.
DISCUSSION
Mutations in kinases can result in deregulated kinase activity
that can promote diseases such as cancer. Although pharmaco-
logical inhibition with small molecules can lead to tumor regres-
sion, many kinase targets develop resistance through secondary
mutations. Another challenge in the development of kinase
Figure 6. Chemical Modifications Affecting the Potency of 4-Anilinoquinazoline Compounds toward T674I PDGFRa
(A) Remaining kinase activity of T674I PDGFRa in the presence of 4-anilinoquinazolines with substituents in either the meta or para position of the aniline ring.
Horizontal lines represent the mean remaining kinase activity for the grouped data.
(B) Remaining kinase activity of T674I PDGFRa in the presence of 4-anilinoquinazolines containing a para substituent plotted against the molecular weight of the
substituent.
(C) Remaining kinase activity of T674I PDGFRa in the presence of 4-anilinoquinazolines with halogen substituents in either themeta or para positions of the aniline
ring. Horizontal lines represent the mean remaining kinase activity for the grouped data.
(D) Test compounds used to validate the predictions of the 4-anilinoquinazoline pharmacophore hypothesis.
(E–G) IC50 values measured from dose-response curves of the compounds in (D) against T674I PDGFRa in vitro, grouped according to the prediction tested. (E)
Substituents at the meta position of the aniline ring are favored over the same substituents at the para position. (F) Large substituents at the para position of the
aniline ring decrease potency. (G) Smaller/more electronegative halogen substituents at the meta position of the aniline ring decrease potency toward T674I
PDGFRa. Dose response measurements were performed in triplicate. Error bars represent 95% confidence intervals. IC50 values are given in Table S3.inhibitors is the promiscuous nature of these small-molecule
compounds. One way to overcome this challenge is to imple-
ment a ‘‘compound-centric’’ strategy in which compound li-
braries are screened broadly against a collection of kinases
(Goldstein et al., 2008). Compounds that have undesirable off-
target effects are readily identified and eliminated, whereas
those with the most promising target spectrum and selectivity
are chosen for further analysis and development.
Here, we employed a compound-centric approach to identify
inhibitors of disease-associated mutant kinases. We screened
a diverse collection of 183 small-molecule kinase inhibitors
against 76 mutated kinases derived from 21 cognate wild-type
kinases. Initial analysis of the data revealed many unexpected
compound/kinase interactions. We found that EGFR/ErbB2/CErbB4 inhibitor targets the highly resistant T790M EGFR muta-
tion with similar potency as afatinib, a structurally related
EGFR inhibitor that is FDA-approved. In profiling studies against
a panel of 300 wild-type kinases, this compound had notably
less off-target activity than afatinib. We also identified opportu-
nities for repurposing FDA-approved kinases for targets other
than their intended target. These included several clinical agents
that were designed against other targets but also inhibit T674I
PDGFRa, a mutation present in imatinib-resistant CEL express-
ing the FIP1L1-PDGFRa fusion protein. We also identified com-
pounds with activity against ALK, LRRK2, and RET mutant
kinases.
In addition to the specific kinase/compound pairs discussed
here, we expect that the dissemination of this dataset will leadell Reports 14, 772–781, February 2, 2016 ª2016 The Authors 779
to the evaluation of other previously undescribed kinase/com-
pound interactions. The robust quantitative data presented
here for mutant kinases, taken together with prior studies
focused primarily on wild-type kinases (Anastassiadis et al.,
2011; Davis et al., 2011; Fabian et al., 2005; Gao et al., 2013;
Karaman et al., 2008), represent a rich resource for compound
repurposing and for understanding inhibitor potency and
selectivity.
The value of this large dataset rests not only in the identifica-
tion of potent inhibitors of mutant kinase targets but also in
the information provided by compounds with weaker inhibitory
activity. Indeed, we illustrated, using T674I PDGFRa, that the
aggregate data for 13 4-anilinoquinazoline compounds ranging
in potency against this mutant kinase provides predictive struc-
ture-activity information to guide subsequent medicinal chemis-
try efforts. These data are particularly useful in the development
of inhibitors for kinases like T674I PDGFRa, for which structural
data are lacking. We were able to predict the effects on potency
against T674I PDGFRa of chemical modifications to the aniline
ring of 6,7-dimethoxy-4-anilinoquinazoline and confirmed these
predictions experimentally. Overall, we suggest that large-scale
profiling studies using both wild-type and mutant kinases and
compound collections of diverse but densely sampled scaffolds
will provide the most information-rich approach to compound-
centric kinase inhibitor development.
EXPERIMENTAL PROCEDURES
Materials
The majority of kinase inhibitors have been described in a previous study
(Anastassiadis et al., 2011). In addition to this set, five additional compounds
were profiled: Aurora kinase inhibitor II (CAS no. 331770-21-9, purchased
from EMD Biosciences), irfin1 (Anastassiadis et al., 2013; CAS no. 1177970-
73-8, purchased from EMD Biosciences), and afatinib (CAS no. 850140-
72-6, purchased from LC Laboratories). Olaparib (CAS no. 763113-22-0,
purchased from LC Laboratories) and vismodegib (CAS no. 879085-55-9, pur-
chased from LC Laboratories) were included as control compounds. For the
dose-response measurements involving 6,7-dimethoxy-4-anilinoquinazoline
derivatives, the masses and purities of AG-1478 (CAS no. 153436-53-4, pur-
chased from Selleckchem), CHEMBL94431 (CAS no. 202475-55-6, pur-
chased from Key Organics), EGFR/ErbB2 inhibitor (CAS no. 179248-61-4,
purchased from EMD Biosciences), Janex 1 (CAS no. 202475-60-3, pur-
chased from Cayman Chemical), PD153035 (CAS no. 183322-45-4, pur-
chased from Selleckchem), Src kinase inhibitor I (CAS no. 179248-59-0, pur-
chased from EMD Biosciences), and WHI-P180 (CAS no. 211555-08-7,
purchased from EMD Biosciences) were confirmed by LC-MS (Waters 2545
binary gradient module, 3100 mass detector, 2487 UV detector set to 254
and 280 nm, and 2424 ELS detector) using a Delta Pak C-18 column
(100 A˚, 15 mm, 3.9 3 300 mm). Samples were analyzed using a 5%–95%
acetonitrile gradient with 0.05% formic acid over 15 min. A description of
the kinase constructs and expression systems used for these constructs is
given in Table S1.
In vitro Kinase Assays
The Reaction Biology (http://www.reactionbiology.com) HotSpot assay plat-
form was used to measure kinase/inhibitor interactions as described
previously (Anastassiadis et al., 2011). In brief, for each reaction, kinase and
substrate were mixed in a buffer containing 20 mM HEPES (pH 7.5), 10 mM
MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na3VO4, 2 mM
DTT, and 1% DMSO. Compounds were then added to each reaction mixture.
After a 20-min incubation, ATP (Sigma-Aldrich) and [g-33P] ATP (PerkinElmer)
were added at a final total concentration of 10 mM. Reactions were carried out
at room temperature for 2 hr and spotted onto P81 ion exchange cellulose780 Cell Reports 14, 772–781, February 2, 2016 ª2016 The Authorschromatography paper (Whatman). Filter paper was washed in 0.75% phos-
phoric acid to remove unincorporated ATP. The percent remaining kinase ac-
tivity relative to a vehicle-containing (DMSO) kinase reaction was calculated
for each kinase/inhibitor pair. Outliers were identified and removed as
described previously (Anastassiadis et al., 2011). Data were subjected to hier-
archical clustering as described previously (Anastassiadis et al., 2011). IC50
values were calculated using Prism 5 (GraphPad).
Cell Viability Measurements
Cell viability measurements were carried out using the CellTiter-Glo lumines-
cent cell viability assay (Promega) according to the manufacturer’s instruc-
tions. Briefly, 10,000 cells were plated in each well of a 96-well plate.
Compounds were added to cells, resulting in a DMSO concentration of
0.5% in each well. At 24 hr, CellTiter-Glo reagent was added, and lumines-
cence was measured using an EnSpire multimode plate reader (PerkinElmer).
Data were fit to sigmoidal dose-response curves using Prism 5 (GraphPad).
SUPPLEMENTAL INFORMATION
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four figures, and seven tables and can be found with this article online at
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